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SURVEY 
Insulin-like Growth Factor Binding Proteins and their Role in 
Controlling IGF Actions 
David R Clemmons 
The insulin-like growth factor binding proteins (IGFBPs) are a family of six proteins that bind to 
insulin-like growth factor-I and -II with very high affinity. Because their affinity constants are 
between two- and S0-fold greater than the IGF-I receptor, they control the distribution of the IGFs 
among soluble IGFBPs in interstitial fluids, IGFBPs bound to cell surfaces or extracellular matrix 
(ECM) and cell surface receptors. Although there are six forms of insulin-like growth factor binding 
proteins, most interstitial fluids contain only three or four forms, and usually only one or two 
predominate. The proteins differ significantly in their biochemical characteristics, and this accounts 
for many of the differences that have been observed in their biological actions. Several different 
types of protease cleave these binding proteins. Proteolytic cleavage generally inactivates the binding 
proteins or reduces their ability to bind to IGF-I or -II substantially. Several cell types have been 
shown to secrete these proteases; therefore, the factors that regulate protease activity can control 
binding protein actions indirectly. Other post-translational modifications, such as glycosylation and 
phosphorylation, have been shown to alter IGF binding protein activity. While binding protein 
actions have been studied extensively in vitro, many of the in vivo activities of these proteins remain 
to be defined. , ~997 Elsevier Science Ltd All rights reserved 
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The insulin-like growth factor binding proteins (IGFBPs) The nomenclature used to name the IGF binding pro- 
were originally discovered while attempting to purify teins was developed as a result of the historical order in 
insulin-like growth factor-I (IGF-I) from serum [1, 2]. which these sequences were identified. IGFBP-1 was the 
Chromatographic studies howed that most of the IGF- first to be purified and sequenced because of its abun- 
I in serum had a molecular weight estimate of 150 kDa dance in amniotic fluid [4, 5]. This was followed by DNA 
by neutral gel filtration chromatography, even though the sequencing which was used to determine the entire amino 
purified material was later discovered to have a molecular acid sequence [6, 7]. The cloning and sequencing of rat 
weight of 7649. This difference was suspected to be due IGFBP-2 followed shortly thereafter [8]. IGFBP-3, which 
to binding protein activity since acid gel filtration chro- had been purified to homogeneity from serum [9], was 
matography resulted in dissociation ofthe IGF biological cloned and sequenced [10]. Subsequently, Ling and 
activity from higher molecular weight proteins [2]. Later, coworkers reported the sequences of IGFBP-4, -5 and -6 
reconstitution experiments showed that the IGF-binding [11]. 
protein complex could reform if the acid gel filtration During attempts to purify these materials, specific anti- 
separated fractions were recombined [3]. This led to sera for IGFBP-I and-3 were developed that allowed the 
attempts to purify the binding activity from serum and measurement of these proteins in physiological fluids [12, 
amniotic fluid. 13]. Subsequently, the development ofcDNA probes and 
antibodies for all six binding proteins further facilitated 
work in this area. This has led to the rapid accumulation 
Department ofMedicine, University ofNorthCarolina, School of information regarding the factors that control their 
of Medicine, CB #7170, Chapel Hill, NC 27599, U.S.A. Tel.: synthesis, ecretion and distribution among tissues as well 
(919) 966-4735: Fax: (919) 966-6025. as target cell actions [14]. 
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CONTROL OF IGF BINDING PROTEIN SYNTHESIS complementary to that of IGF-II [30]. In contrast, 
AND SECRETION IGFBP-4 is found to be widely expressed in multiple 
subsets of mesenchymal cells. IGFBP-5 is expressed as 
The factors that regulate IGF binding protein synthesis early as day 10 in specific regions of surface ctoderm, in 
by specific cell types are major determinants of the tissue muscle all precursors and differentiating somites, noto- 
distribution of IGF-I and -II. Both IGF-I and IGF-II chord and the foreplate regions of neuroepithelium [30]. 
have important autocrine/paracrine actions, particularly Likewise, specific neuronal populations, uch as the olfac- 
during fetal life [15] and during tissue repair after injury tory bulb, also express this form of IGFBP. Expression 
[16]. Gene targeting experiments have shown that oflGFBP-6 does not begin until day 15. It is localized to 
reduced expression of pituitary growth hormone results cells surrounding developing cartilage. 
in dwarfism in mice and that restoration of IGF-I Expression of IGFBPs changes quite significantly in 
secretion by transgenic manipulation can restore normal many tissues during the fetal to adult transition. IGFBP- 
growth [17]. Similarly, gene targeting IGF-I of IGF-II 2 mRNA is abundant in late fetal rate liver but is 
results in 40-50% reduction in size at birth [18], and extremely low in adult rat liver [22]. In contrast, IGFBP- 
IGF-I deletion also results in further postnatal growth 4 mRNA, which is low in the fetal liver, increases ub- 
attenuation [19]. A large percentage of this reduction is stantially in the adult. The converse is true for kidney 
believed to be due to the loss of the autocrine or paracrine wherein it is expressed in fairly high levels in the fetus, 
actions of the IGFs within tissues; therefore, the factors but undetectable in the adult. The developmental changes 
that control tissue IGF concentrations are important for in cell-type specific expression of IGFBP-5 have been 
normal growth, extremely well characterized in brain, kidney and ovary. 
Although all cells and tissues that have been examined The functional consequences of these changes have not 
synthesize at least one form of IGFBP, the general pat- been determined. 
tern is that each tissue or cell type synthesizes different 
combinations. Therefore, mesenchymal cells, such as CONTROL OF IGFBP CONCENTRATIONS IN 
fibroblasts, synthesize IGFBP-3, -4 and -5 [20], whereas BLOOD AND REGULATION OF THE ENDOCRINE 
epithelial cells usually synthesize more IGFBP-2 and -4. ACTIONS OF IGF-I AND -II 
Similarly, within organs, there may be discrete regions 
that localize specific forms of IGFBPs such as, local- The endocrine actions of IGF-I and -II are also necess- 
ization of IGFBP-5 within the olfactory bulb [21]. The ary for normal postnatal growth and development. 
exact physiological significance of such discreet regional Secretion of IGF-I and -II by the liver into the circulation 
specificity has not been determined. The regulation of is under the control of pituitary growth hormone, and this 
synthesis of IGFBPs by specific ell types has been studied is believed to be the origin of the IGFs in the circulation. 
intensely and is beyond the scope of this review. An Ablation ofthissourcebyhypophysectomyorGHrecep- 
excellent summary of this information isa comprehensive tor mutations results in decreased IGF-I mRNA in liver 
review by Rechler [22]. and growth retardation [31, 32]. Since, following the entry 
Generally, IGFBP secretion by cells in culture has been into the circulation, the IGFs immediately bind to 
analysed using the technique known as ligand blotting IGFBPs, the factors that control IGFBP concentrations 
[23]. Some authors have studied synthesis using metabolic in blood are also potential endocrine regulators of IGF 
labeling and immunoprecipitation [24] and other inves- actions. In order to understand the endocrine actions of 
tigators have studied the effect of various factors on both IGF-I and -II, it is necessary to understand the role 
mRNA abundance, mRNA stability or direct analyses of of traditional hormones in controlling IGFBP synthesis 
gene transcription [25-27]. In general, these studies have by the liver and their secretion into the circulation. 
been successful in identifying many factors that stimulate 
synthesis of individual forms of binding proteins, and IGFBP-1,-2 and-3  
there are multiple examples of factors such as retinoic 
acid that are potent stimuli of synthesis of one particular The principal carrier of IGF-I and -II in serum is 
protein but have no effect on synthesis of another form IGFBP-3 [33]. It is synthesized in the liver, by non- 
that is constitutively synthesized by the same cell type parenchymal cells [34]. The endothelium ay also be an 
[28]. important source [35]. Because of its high affinity con- 
stant which is 10- to 20-fold greater than either IGFBP- 
TISSUE EXPRESSION OF IGFBPs 1 or -2, the other major forms oflGFBPs in serum (Table 
1), it binds 90-96% of IGF-I and -II. Its molar con- 
Analysis of mid-gestational rats has shown that centration is usually nearly equal to the sum of IGF-I 
IGFBP-1 expression is restricted to the liver [29]. In con- plus IGF-II. The blood concentrations of IGFBP-3 are 
trast, IGFBP-2 expression is very high in tissue types regulated by age, nutrition and the hormonal milieu [36]. 
derived from ectoderm and endoderm, but there is very Growth hormone (GH) is the major hormonal factor 
little mesodermal expression. IGFBP-3 expression occurs controlling its concentration. Plasma IGFBP-3 levels are 
primarily in mesoderm, but it is restricted to a specific elevated in patients with acromegaly, and low in patients 
subset of mesenchymal cells. Its expression pattern is with hypopituitarism. GH directly stimulates IGFBP-3 
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Table 1. Post-translational modifications 
Structural 
characteristics IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6 
Glycosylation - - N N O O 
Heparin binding - +~ + - + ND 
Phosphorylation + - + - + N D 
Proteolysis - + + + + ND 
Cell surface ECM localization - + + - + - 
RGD sequence + + . . . .  
"Only if IGF-I or IGF-II is present. 
ND: not determined. 
synthesis, and factors that attenuate growth hormone [40]. This results in retention of the IGFBP-3 that is 
action result in a major decrease in its concentration contained within the complex and reduces the clearance 
in blood. IGF-I  is a secondary regulator and has been rate of the IGFs. In general, most of the IGF-I  and -ll 
reported to increase IGFBP-3 blood concentrations in (>90%)  in serum is bound to this complex, although 
rodents [22]. However, the effects of IGF- I  are complex some IGF is present bound to IGFBP-3 that is not associ- 
because it allows binding of a third protein, termed acid ated with the complex and to other forms of IGFBPs. 
labile subunit (ALS) to the IGFBP-3/ IGF complex [37]. Although IGF-1 can also stimulate an increase in IGFBP- 
This acts to stabilize the IGF- I / IGFBP-3 complex and 3, free IGF-I  suppresses GH which is necessary to main- 
prolong its half life, but whenever IGF- I  concentrations tain normal ALS levels. Therefore, high dose admin- 
exceed the IGFBP-3 binding capacity, they act indirectly istration of IGF-I  will result in decreased ALS and 
(see below) to suppress ALS. Therefore, the role of IGF- ultimately in decreased levels of IGFBP-3. This results in 
1 appears to be maintenance of IGFBP-3 concentrations, a smaller pool of plasma IGF and an attenuated response 
Hormones other than GH also influence the synthesis in terms of protein synthesis and protein balance. Ani- 
and secretion of 1GFBP-3 [22, 31], which is low in pre- reals that are treated with GH intravenously show a 
pubertal males and is increased following testosterone two-fold increase in ALS concentrations, and a four-fold 
administration. IGFBP-3 concentrations are 40% lower increase in ALS mRNA [39]. Severe insulin depletion 
following menopause and can be increased to pre- results in decreased ALS synthesis, possibly leading to 
menopausal levels in postmenopausal females with phy- the reduction in serum IGF-I  levels seen in diabetes, and 
siologic estrogen administration. Thyroxine controls insulin is necessary for hepatocytes to maintain normal 
IGFBP-3 concentrations, which are lowin primary hypo- ALS synthesis in vitro. Glucocorticoids uppress ALS 
thyroidism and increase to approximately 55% following mRNA synthesis and fasting results in a decrease in ALS 
adminstration of thyroxine. Insulin may have a role in concentrations [39, 41]. Therefore, ALS appears to be 
maintaining plasma IGFBP-3 concentration, since it regulated parallel with IGFBP-3 and to someextent with 
improves the IGFBP-3 synthesis response to GH, but it IGF-I. 
does not appear to have a direct effect. In summary, several factors function coordinately to 
Coordinate regulation of IGF-I  and IGFBP-3 is an maintain near equimolar concentrations of the sum of 
important mechanism for maintaining an adequate res- IGF-I,  plus IGF- I I  with IGFBP-3. These include rapid 
ervoir of IGF-I  in the vasculature. When IGF-I  synthesis clearance of free IGF, a coordinate increase in the syn- 
is increased by GH, there is a concomitant increase in thesis of IGF-I, IGFBP-3 and ALS in response to GH 
IGFBP-3 and therefore in 1GF binding capacity. In and maintenance of the ternary complex by IGF-I  or 
addition to these two proteins, the IGF/ IGFBP-3 corn- IGF-I I  binding. Although binary complexes of IGF-1 or 
plex binds to the acid labile subunit, and these three IGF-I I  and 1GFBP-3 form in the serum, they constitute 
proteins constitute the stable 150,000-Da ternary a small percentage of the total IGF concentration. 
complex. The synthesis ecretion of ALS is dependent IGFBP-2 is the second most abundant form of IGFBP 
upon GH and it is not increased by IGF-I.  However, in serum. Its affinity for IGF-I I  is four-fold higher than 
since IGF-I  or IGF-I I  binding to IGFBP-3 facilitates its its affinity for IGF-I. This protein does not form a ternary 
binding to ALS, an increase in IGF-I  will act to stabilize complex with any other protein and circulates associated 
the three proteins and prolong their half-lives [38]. in a binary complex with either IGF-I  or IGF-I I  [42]. 
GH directly stimulates ALS synthesis in hepatocytes This complex has a molecular weight estimate of 40 
[39]. A major function of the IGFBP-3/ALS complex is 50 kDa. The IGFBP-2 that is present in the circulation 
to prolong the half lives of IGF- I  and -II in the vascu- originates from hepatocytes, and the abundance of 
lature. ALS functions to attenuate transport of the binary IGFBP-2 mRNA in liver is regulated in parallel with its 
IGF/1GFBP-3 complex out of the vasculature. While free plasma concentrations. GH is a determinant of IGFBP- 
IGFBP-3 is cleared from serum with a half-life of 1 2 h, 2 plasma concentrations, and they are inversely related 
the ALS/ IGFBP-3/ IGF complex has a half-life of 16 h to the ambient level o fGH.  IGF-I is a potent stimulant of 
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IGFBP-2 concentrations in serum [43]. Generally, there is increase that occurs in serum insulin concentrations 
an excess of IGFBP-2 binding capacity in serum, and, results in a four- to five-fold decrease in IGFBP-1 [48]. 
therefore, it can act as a reservoir for free IGF-I following This change is due to a direct suppression of IGFBP-1 
acute IGF-I administration. Plasma IGFBP-2 con- synthesis in the liver [48]. IGFBP-1 mRNA abundance 
centrations also appear to be increased by IGF-II, par- in liver has been shown to decrease after administration 
ticularly in patients with non-islet cell tumor of insulin to diabetic or normal animals. This change is 
hypoglycemia (tumors that produce IGF-II) [44]. due to direct effect of IGFBP-1 transcription, and there 
Hepatic IGFBP-2 mRNA expression is increased sig- is an insulin response lement in the 5' flanking region of 
nificantly in diabetic rats and suppressed with insulin the IGFBP-1 gene [49]. This element has a consensus 
administration [45]. This finding is not mimicked in sequence that is similar to the insulin response lement 
humans, however, who show no significant increases in in the PEPCK gene and mediates the effect of insulin on 
serum IGFBP-2 concentrations unless they are also sev- transcription [50]. IGFBP-1 has also been shown to cross 
erely malnourished, and IGFBP-2 levels are not acutely intact capillary beds, and the amount hat crosses in a 
suppressed in patients with Type I diabetes by insulin, fixed time period is dependent upon the ambient insulin 
Nutrition is a weak regulator of IGFBP-2 expression, concentration [51]. This provides a second mechanism by 
IGFBP-2 gene transcription is increased in starved rod- which insulin can decrease serum IGFBP-1. The func- 
ents and plasma concentrations are increased in fasted tional consequences of this large change in IGFBP-1 on 
humans [46]. This change is slow, and it takes 6 days for IGF-I stimulated glucose disposal are not well defined. 
levels to reach their maximum. The principal nutrient Lewitt et al. showed that acute administration of a large 
that appears to be involved is protein since moderate excess of IGFBP-1 to normal rats resulted in a slight 
caloric restriction in normal human subjects does not increase in blood glucose [52]. However, the manner in 
result in any significant change in IGFBP-2 concen- which this protein functions in the usual physiological 
trations, but severe protein deprivation results in a 3(~ situation where there is a relatively low concentration of
40% increase. Strauss et al. have shown that the hepatic unsaturated IGFBP-1 (e.g. only enough to bind 2-5 
IGFBP-2 mRNA increases with protein restriction, and ng/ml of IGF-I) is not entirely clear. 
this change is reversible with protein refeeding [47]. In addition to decreasing after insulin administration, 
IGFBP-2 has also been shown to be regulated by thy- IGFBP-1 levels also correlate with changes in insulin 
roxine. Thyroxine administration to hypothyroid animals sensitivity. IGFBP-1 levels are elevated in Type I diabetes 
results in a small increase in IGFBP-2. Data with sex and are lowered after administration of insulin. Fasting 
steroids, such as androgens, have not been reported. Glu- for relatively short periods, e.g. 12-14 h, results in a four- 
cocorticoids suppress IGFBP-2 synthesis n mesenchymal to six-fold increase in IGFBP-1 concentrations, probably 
cells, but have minimal effects on serum IGFBP-2 levels. due to suppression of insulin [46]. In states of insulin 
GH regulation of IGFBP-2 has been demonstrated in resistance, IGFBP-1 levels are elevated but return to nor- 
experimental nimals. Hypophysectomy in rats results in 
a 10- to 20-fold increase in IGFBP-2 mRNA in the liver, mal when these states are ameliorated. GH suppresses 
and plasma levels are also concomitantly increased [25]. IGFBP-1, and its levels are elevated in children or adults 
with GH deficiency [48, 53]. Similarly, hypophysectomy in pigs results in a substantial 
In addition to insulin, glucocorticoids that are counter- increase. Insulin deficiency also results in an increase in 
plasma IGFBP-2 in rats, and readministration f insulin regulatory hormones opposing insulin action have the 
to diabetic animals results in a decrease. However, opposite effect on IGFBP-1 synthesis. Specifically, glu- 
cocorticoid administration to animals results in increased humans with poorly controlled Type I diabetes do not 
have an increase in plasma IGFBP-2. GH administration serum IGFBP-I concentrations [54, 55]. In cell culture, 
to humans results in a substantial lowering of plasma IGFBP-1 gene transcription has been shown to be 
IGFBP-2 [46]. The effect of GH appears to be mediated directly enhanced by glucocorticoid addition, and insulin 
independently of insulin. That this is a direct effect of reverses this effect in a dominant negative manner [24]. 
GH is suggested by the observation that administration More recently, a glucocorticoid response lement in the 
of GH to patients with GH receptor mutations does not 5' flanking region of the IGFBP-1 gene has been identified 
result in such a decrease [32]. [49]. In addition, there is direct interaction between insu- 
The IGFBP-1 that is present in the circulation is also lin and glucocorticoids in regulating IGFBP-1 tran- 
synthesized in the liver. In situ hybridization studies have scription. Glucocorticoid-mediated in uced IGFBP-1 
shown that the liver, maternal placenta nd uterus are transcription is also dependent upon hepatic nuclear fac- 
the only major sites of synthesis [22]. Hepatic synthesis tor 3 (HNF-3) and an intact HNF sequence is required 
of IGFBP-1 is primarily under the control of insulin, for glucocorticoids to stimulate and for insulin to inhibit 
although other hormones uch as GH and cortisol also IGFBP-1 promoter activity [56]. Thus, plasma levels of 
participate. In contrast to IGFBP-3, a substantialportion IGFBP-1 appear to be regulated predominantly at the 
of IGFBP-1 and -2 in blood is unsaturated. Therefore, level of hepatic mRNA synthesis. The exact role by which 
they have been postulated to be the major modulators of these hormonally induced changes in IGFBP-1 modify 
free IGF levels. Insulin is the major determinant of IGF-I and-I I  actions to alter carbohydrate metabolism 
plasma IGFBP-1 concentrations. The post-prandial requires further analysis. 
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IGFBP-4,-5 and-6 boxyl terminal ends, have some IGF binding activity 
[59]. Fragments that contain only the cental core of the 
The serum concentrations of intact IGFBP-4are quite molecule that is not conserved have no IGF binding 
low, and the role of this peptide in regulating IGF activity. 
bioavailability from vascular sources in unclear. The only Another conserved element of interest is the Arg-Gly 
major hormone that has been shown to regulate IGFBP- Asp sequence that is located in the carboxyl terminus of 
4 concentrations in serum is the parathyroid hormone. IGFBP-1 and -2. IGFBP-1 has been shown to bind to 
Mohan and coworkers howed that, in states of low bone the e5fll integrin through this sequence [60]. Radio- 
turnover and low parathyroid hormone concentrations, labeling of both human fibroblast and porcine aortic 
serum IGFBP-4 concentrations were increased [57]. Simi- smooth muscle cell surface proteins followed by immu- 
larly, other investigators have shown some correlation noprecipitation with anti-integrin antibodies hows that 
with sunlight exposure suggesting that vitamin D or one multiple integrins are present. However, ~5/~1 is on the 
of its active metabolites also may regulate serum IGFBP- integrin that binds to IGFBP-I. IGFBP-2 does not bind 
4. Since IGFBP-4 is a potent inhibitor of IGF acitivty in to cdfll, suggesting that it is folded in such a way that its 
bone, this suggests that serum IGFBP-4 concentrations RGD sequence cannot bind to this integrin. 
may be linked to the control of the trophic effects of IGF- The central nonconserved region of the IGFBPs also 
1 on bone metabolism, has an important physiological role. All of the IGFBPs 
Studies to determine the variables that regulate the are cleaved by proteases, and proteolysis results in the 
serum concentrations of IGFBP-5 and -6 are limited, loss of IGF binding affinity. Most of the proteolytic cleav- 
Although these proteins are detectable in serum, their age sites that have been identified to date are within 
concentrations are extremely low, and it is difficult, at the nonconserved region [61]. Therefore, it is likely that 
this time from the available published data, to present protease specificity is due in part to the presence of these 
an organized theory as to how changes in their serum nonconserved sequences. Since distinct proteases have 
concentrations might alter IGF action. Additionally, been identified for IGFBP-2, -3,-4, and-5, it is likely that 
IGFBP-5 is synthesized principally by connective tissues, these proteases use unique cleavage sites. This has the 
and the protein has several characteristics (to be reviewed potential to provide a physiological mechanism by which 
below) that inhibit its ability to enter the vascular space, the activities of IGFs are regulated in a tissue or cell-type 
specific manner. 
PROTEIN STRUCTURES AND FUNCTIONAL Two IGF-binding proteins, e.g. IGFBP-3 and -4, have 
RELATIONSHIPS been shown to undergo N-linked glycosylation. IGFBP- 
3 contains three putative N-linked glycosylation sites, of 
The amino acid sequences of the six forms of IGF which at least two have been shown to be used. IGFBP- 
binding proteins are shown in Figure 1. Analysis of the 4 contains one consensus ite which is also used. Both 
sequence alignment of these proteins hows several corn- 1GFBP-5 and -6 have been shown to be O-glycosylated. 
mon and yet distinct structural features. Each protein The biologic significance of both O- and N-glycosylation 
contains a leader sequence with a hydrophobic domain, for these proteins is undefined. 
and all are known to be synthesized and secreted by at 
least one cell type. The proteins vary in length from 216 
amino acids (IGFBP-6) to 289 amino acids (IGFBP-2). VARIABLES THAT REGULATE THE AFFINITIES OF 
All six proteins contain 18 cysteines that are conserved. THE VARIOUS FORMS OF IGFBPs 
IGFBP-4 contains two additional cysteines in the central 
core of the molecule. There is a great deal of conservation One of the most important observations regarding 
of sequence in both the amino and carboxyl terminal IGFBPs is their high affinity for IGF-I and -II. IGFBP- 
regions. The region containing the first 10 cysteines in 3 and -5 have the highest affinity. These estimates vary 
the amino terminal domain is highly conserved. In the between being two- and 50-fold greater than the Type i 
region between cysteines 5 and 11, 21 and 29 amino IGF receptor. The biological implications of this high 
acids are conserved in five of the six proteins. The region affinity are obvious since soluble high-affinity IGFBPs 
between cysteines 12 and 18 is also conserved. The region will prevent receptor association. The importance of 
between cysteines 14 and 17 contains 17 of 28 amino changes in the affinities for IGFBPs is that, under specific 
acids that are identical in at least five of the six forms of situations where their affinities are lowered significantly, 
IGFBPs. Although the exact linear sequences responsible they can provide a stable reservoir of IGF that is in a 
for IGF binding have not been identified, it is presumed more favorable quilibrium with receptors and, therefore, 
that a combination of these conserved sequences plus a capable of stimulating rowth and anabolic functions. 
specific folding pattern is required for IGF recognition. Additionally, they may prevent clearance of IGF from 
Data to support his conclusion include experiments in tissues, thereby providing a more stable reservoir. There- 
which the disulfides have been reduced and then scram- fore, it has been of interest o determine the variables 
bled. These altered forms bind IGF-I poorly [58]. Simi- that regulate IGFBP affinity. 
larly, fragments of the protein that contain intact To date, three factors have been shown to dramatically 
intrachain disulfide bonds, but only the amino or car- alter affinity of lGFBPs (Table l). The first is proteolysis. 
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Figure 1. The amino acid sequences of the human IGF binding proteins are shown. ]he amino acids that are identical in at least 
four of the six IGFBPs are shaded. The asterisk indicates conserved cysteines. The RGD sequences in the IGFBP-1 and -2 are 
boxed. The N-glycosylation sites in IGFBP-3 and -4 are underlined. 
Although proteolytic cleavage may result in the gen- proteolysed complex did not, suggesting that proteolysis 
eration of fragments that have no affinity for IGF, it had altered the affinity of IGFBP-3 for IGF-I. Recently, 
has also been shown to result in fragments that have these earlier observations have been clarified by showing 
significantly lower affinity, and binding to these lower that the principal fragment of IGFBP-3, that is the 30- 
affinity fragments has been shown, in some cases, to result kDa fragment hat is generated, can still bind to IGF-I 
in potentiation of the effect of IGF-I.  Similarly, phos- or IGF-I I ,  but with reduced affinity [68]. This binary 
phorylation of IGFBP-1 has been shown to increase its complex is still capable of binding to ALS [69]. 
affinity for IGF-I  by approximately six-fold [62]. The Subsequently, it was determined that both human and 
lower affinity nonphosphorylated forms of IGFBP-1 rat pregnancy serum contained high concentrations of a 
have been shown, under certain culture conditions, to protease that cleaved IGFBP-3 [70-72]. The technique of 
enhance the effect of IGF-I  on smooth muscle cell and ligand blotting had been developed at that time, and this 
fibroblast replication [63]. Finally, adherence to either technique was used to show that the remaining IGFBP-3 
cell surfaces or the extracellular matrix has been shown fragments had significantly reduced affinity for IGF-I. 
to be associated with a lowering of IGFBP affinity and Incubation of intact IGFBP-3 with pregnancy serum con- 
potentiation of IGF action [64-66]. Therefore, the vari- taining the protease in t:itro, followed by immunoblotting, 
ables that regulate the affinity of these proteins may be confirmed that the size of IGFBP-3 had shifted protein 
important determinants of IGF action at the cellular from 46 to 30 kDa. This protease was found to be a 
level, cation-dependent serine protease. Subsequent studies 
have shown that matrix metalloproteases, principally 
Proteo lys i s  MMP1 and MMP2, which are also present in human and 
rat pregnancy serum, can degrade IGFBP-3 [73]. Unlike 
The initial studies of IGFBP proteases were directed the serine protease activity, these proteases are not spec- 
toward the analysis of lGFBP-3 proteolysis since IGFBP- ific for IGFBP-3 but will degrade other forms of IGFBPs. 
3 is the predominant form in serum. It was shown that a The exact sites of MMP cleavage have not been deter- 
divalent dependent protease activity existed in normal mined; however, it has been shown that they are in the 
serum, but following proteolysis of the 150K complex, central core (nonconserved region) of IGFBP-3. Pro- 
IGF-I  and -II remained associated with this complex, teolytic activity increases as a function of gestation in the 
although the affinity of the IGFBP for IGF- I  was reduced rat, and there is much more activity in the latter part of 
[67]. Treatment with heparin (a strong cationic agent) pregnancy than the first half of pregnancy. In humans, 
resulted in dissociation, whereas treatment of the non- this time-dependent change in IGFBP-3 proteolysis i less 
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important, and the activity is high throughout gestation. IGFBP-2 from the circulation and therefore decrease the 
The change in MMP activity may be due to the decline half-life of IGF-I. Levels of this protease are increased 
in tissue inhibitor of metalloprotease that occurs during during starvation [83]. Unlike the IGFBP-3 protease, this 
pregnancy. Plasmin has been proposed to be one of the activity could not be demonstrated in vitro and is solely 
IGFBP-3 proteases in pregnancy serum [74]. However, an in vivo phenomenon, suggesting that the protease is 
free plasmin is not present in plasma, and, therefore, not released into the serum [83, 84]. Children with severe 
the degradation caused by plasmin would have to occur protein calorie malnutrition have been shown to have 
during placental passage. Although normal plasma con- significant cleavage of IGFBP-2 [85]. Food deprivation 
tains very little detectable IGFBP-3 protease, proteolytic of new born pigs also results in the appearance of IGFBP- 
activity can be detected in a variety of conditions other 2 proteolytic activity in serum [84]. 
than pregnancy. In GH deficiency, there is increased An IGFBP-2 specific serine protease has been shown 
IGFBP-3 protease activity [75]. Likewise, after stresses to be present in culture supernatants of aortic smooth 
such as the induction of surgery or acute medical illnesses, muscle cells [86]. This serine protease is inhibitable with 
there is an increase in proteolytic activity in serum [76, multiple members of the serpin inhibitor family, including 
77]. Fasting induces proteolysis, as does non-insulin- heparin cofactor II and anti-thrombin-III. Heparin also 
dependent diabetes, directly inhibits the activity of this protease. The effect of 
The consequences of proteolysis of serum IGFBP-3 these serpins can be potentiated in the presence of 
are less well understood. Since the 30-kDa fragment of heparin. It has a molecular weight estimate of 37 kDa. 
IGFBP-3 that is detected has a 20- to 30-fold reduction in To cleave IGFBP-2 optimally, the protease requires the 
affinity for IGF-I, it has been proposed that the remaining presence of either IGF-I or IGF-II binding to IGFBP- 
IGF-I that is bound is in more of a nearly complete 2. If neither is bound to the substrate, then proteolysis 
equilibrium with the extravascular tissues. Binoux has proceeds at a very slow rate. The fragments that are 
shown that the IGF-I that is bound to the 150-kDa corn- generated are identical in size to those that are present 
plex following proteolysis i in much better equilibrium in pig serum after starvation, suggesting that the same 
with other binding proteins in serum and the IGFs in protease may be accounting for its cleavage. The protease 
extravascular space [78]. This may be an important mech- is specific for IGFBP-2 and does not degrade other forms 
anism for providing IGF to extracellular tissues during of IGFBPs. The IGFBP-2 fragments that are generated 
times of stress when the protease activity is abundant, do not have the capacity to bind to either IGF-I or IGF- 
Certain proteases that exist in serum other than plas- II; therefore, proteolytic leavage may be necessary for 
min have been shown to degrade IGFBP-3. One is pros- 1GF-I and -II to access receptors, although this has not 
rate specific antigen (PSA), which is present in high been definitely proven. 
concentrations in patients with disseminated prostate Like IGFBP-2 and -3, IGFBP-5 is also proteolytically 
cancer [79]. The other specific protease that degrades cleaved [87]. One of the unique properties of IGFBP-5 is 
IGFBP-3 is Cathepsin-D [80]. However, the role of its ability to associate with the extracellular matrix 
Cathepsin-D in controlling IGFBP-3 abundance in tis- (ECM). When associated with the ECM, it appears to be 
sues remains to be established since this is an intracellular protected from proteolysis. However, when it is present 
cleavage vent. Other than the tissue specific localization in interstitial f uids, it is degraded. The cell types that have 
of the IGFBP-3 pregnancy serum protease activity in been analysed, e.g. fibroblasts, osteoblasts and smooth 
placenta, the origin of most IGFBP-3 protease activity muscle cells, release a serine protease into their medium 
has not been determined. Several cell types, including [20, 87, 88]. Like IGFBP-3, IGFBP-5 is also cleaved by 
fibroblasts, endothelial cells and breast carcinoma cells in MMPs [89]. In fibroblast-conditioned medium, IGFBP- 
culture have been shown to release proteases that cleave 5 is degraded both by a serine protease and by MMPs, 
IGFBP-3. The exact identity of most of these proteolytic but the activity of the MMPs is relatively less compared 
activities and the variables that control their abundance to the serine protease because of the presence of Timp-1 
are unknown at present, and -2, which are also synthesized by these cells. The 
Proteases have been detected in physiologic fluids out- serine protease degrades IGFBP-5 into a major 22-kDa 
side the vascular compartment. Lymph has been shown fragment that has a very weak binding affinity for IGF-I 
to contain high concentrations of IGFBP-3 protease [81]. and -II. Like the IGFBP-2 protease, this serine protease is
This suggests that proteolysis may occur in interstitial inhibited by serpins including anti-thrombin-llI, heparin 
fluids after transport out of the vascular compartment, cofactor 1I and heparin, and its activity can be modulated 
The activity of IGFBP-3 protease has also been studied by these substances in vivo. It has a molecular weight 
in peritoneal fluid, ovarian follicular fluid and synovial estimate of 95 kDa and is specific for IGFBP-5 [90]. 
fluid. Peritoneal fluid contains the greatest amount of Unlike the IGFBP-2 protease, IGF-I and -II binding to 
activity [82]. Joint fluid obtained from patients with IGFBP-5 does not significantly alter the rate of proteo- 
osteoarthritis or rheumatoid arthritis contains con- lysis. Since the identity of the protease has not been 
siderably more proteolytic activity compared to normal established, the variables that regulate activity are 
joint fluid, unknown. However, it is clear that, when there is a high 
Serum has also been shown to contain a protease that ratio of IGFBP-5 to IGF-I, a certain rate of proteolysis 
cleaves IGFBP-2. This would result in rapid clearance of needs to be maintained in order for IGF-I to stimulate 
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cellular esponses. The MMPs that degrade IGFBP-5 in IGFBP-1 phosphorylation in diabetes may be an impor- 
vitro include 52- and 72-kDa gelatinases. An osteoblast tant determinant of IGF-I action in this particular dis- 
cell line (MC 3T3) that was studied by Thrailkill and order [97]. IGFBP-3 has also been shown to be 
coworkers was shown to contain a97-kDa serine protease phosphorylated, but the relative abundance of phos- 
activity and two metalloproteases [89]. All three enzymes phorylated forms of IGFBP-3 has not been determined 
degraded IGFBP-5. [98]. The phosphorylation sites have been identified at 
Proteases for IGFBP-4 are present in several tissue positions 111 and 113, but the identity of the kinase 
culture fluids, including cell culture supernatants from that is responsible for IGFBP-3 phosphorylation a d the 
osteoblasts, neuronal and smooth muscle cells [92-93]. variables that regulate its activity are undetermined. 
The U2 osteosarcoma cell secretes a protease for IGFBP- 
4. Its activity is inhibited by aprotinin and soybean tryp- Adherence to cell surfaces, extracellular matrix and 
sin inhibitor but also by 1,10-phenathroline and EDTA glycosaminoglycans 
[94]. The U2 cell protease requires IGF-I binding to 
IGFBP-4 in order to detect activity. The protease inhibi- Studies that have determined the effect of adherence to
tor data were interpreted to conclude that the U2 con- cell surfaces or to ECM on the affinity of IGFBP-3 and - 
dition media contained a metalloprotease. In contrast, 5 for IGF-I have been reported [66, 84]. Both IGFBP-3 
porcine aortic smooth muscle cells secrete an IGFBP-4 and IGFBP-5 have been shown to adhere to cell surfaces. 
protease that is specific for IGFBP-4 and does not This binding interaction is believed to be mediated for 
degrade other forms of IGFBPs. The activity of this both proteins through proteoglycans. Baxter has shown 
protease is also enhanced by IGF-I binding to IGFBP-4 that proteoglycan binding results in disruption of the 
[94]. It is a calcium-dependent, serine protease, and it has IGF/IGFBP-3/ALS complex, thus resulting in a better 
an estimated molecular weight of 52 kDa. equilibrium with other carriers or extravascular tissues 
[99]. However, IGFBP-3 has also been shown to bind to 
non-proteoglycan-containing proteins on the cell surface, 
Phosphorylation of IGFBPs and one group has presented ata suggesting that this 
may be through a specific ell surface receptor. IGFBP- 
Three of the five forms of IGFBPs have been shown 5, in contrast, binds only to a heparin inhibitable cell 
to be phosphorylated, specifically IGFBP-1, -3 and -5. surface site. Functionally, IGFBP-3 binding to cell sur- 
IGFBP-1 is phosphorylated on serine residues at pos- faces is important because it results in a ten-fold reduction 
itions 101, 119 and 169 by a kinase that is present in CHO in IGFBP-3 affinity of IGF-I [84], and adherence has 
cells and HEP-G2 cells. Phosphorylation i creases the been shown to enhance the effect of IGF-I in stimulating 
affinity of IGFBP-1 for IGF-I by six-fold. This probably AIB uptake by fibroblasts [100]. 
has some physiological significance since different phos- Similarly, IGF-I that is bound to ECM-associated 
phorylated forms have been found in physiological fluids IGFBP-3 or IGFBP-5 is in a more favorable quilibrium 
[62]. In amniotic fluid, most of the IGFBP-1 that is with receptors [66]. IGFBP-5 binding to ECM results in 
detected is in the nonphosphorylated form, whereas an eight-fold reduction in affinity and is associated with 
serum from adult animals contains mostly phos- stabilization of the IGFBP-5/IGF complex such that it is 
phorylated forms. The number of phosphates per resistant to proteolytic cleavage. IGFBP-5 clearly associ- 
IGFBP-1 molecule appears to control the affinity of ates with proteoglycans i  the ECM; however, other non- 
IGFBP-1 for IGF-I since mutagenesis experiments have proteoglycans containing proteins can also bind IGFBP- 
shown that mutants that cannot phosphorylate he 101 5. Adherence to proteoglycans results in a major 
or 169 positions have significantly reduced affinity [95]. reduction (15-fold) in the affinity of IGFBP-5 for IGF-I, 
The relativedegreeofphosphorylationcanbedetected and a modest reduction (three-fold) in the affinity of 
by nondenaturing PAGE which results in separation of IGFBP-3 [101]. The eight-fold reduction in IGFBP-5 
the various phosphoisoforms with different electro- affinity that occurs after ECM association may be 
phoretic mobilities [62]. IGFBP-1 phosphomutants al o required for IGFBP-5 to potentiate IGF action. IGFBP- 
have electrophoretic mobilities that correspond to their 3 binds poorly to the extracellular matrix (ECM) com- 
relative loss of phosphates. The biochemical identity of pared to IGFBP-5, and ECM binding results in a minimal 
the kinase that is present in HEP-G2 cells (probably also change in affinity. Therefore, ECM and cell surface 
present in normal hepatocytes) and that phosphorylates adherence may be important mechanisms by which the 
IGFBP-1 is unknown. Attempts to purify this material effects of these binding proteins modulate the effects of 
showed that casein kinase II is a candidate enzyme and a IGF-I (see below). 
kinase with an Mr estimate of 38 kDa that has bio- 
chemical properties imilar, but not identical to, casein MODULATION OF IGF ACTION BY IGFBPs 
kinase I, was also identified [96]. The hormonal variables 
that regulate these kinase activities are unknown. White The effects of each form of IGFBP and IGF actions 
and coworkers have shown that diabetic serum contains have been studied in detail, but most of the studies have 
a very highly phosphorylated form of IGFBP-1 that has been conducted in vitro using cultured cells. Recently, 
a relatively high affinity for IGF-I and the regulation of some in vivo studies have been forthcoming as well as one 
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significant gene targeting experiment for IGFBP-2. These Four important in-vivo experiments have been con- 
data have allowed a more comprehensive picture of the ducted that have shown inhibitory effects of 1GFBP-1 
role of these proteins in controlling IGF action. Because (Table 2). Lewitt and coworkers injected a very large 
of their relatively high affinities, the IGF binding proteins concentration of IGFBP- 1 that resulted in at least a 10 : 1 
have the potential to control the distribution of the IGFs excess of IGFBP-I to free IGF-I into rats [42]. This 
among soluble forms of IGFBPs, the forms of IGFBPs resulted in a transient increase in blood glucose con- 
that are bound to either cell surfaces or ECM, and cell centration that had returned to normal at a time when 
surface IGF receptors. In addition, by controlling the the ratio had decreased to less than 4: 1. This suggests 
rate of effiux from the vascular compartment and the that, at very high molar ratios, IGFBP-1 can inhibit free 
exposure to renal tubular cells, the principal site of IGF- IGF-I concentrations sufficiently to reduce the effect of 
I degradation and elimination, they have a direct role in free IGF-I on glucose incorporation. Cox and coworkers 
controlling IGF-I bioavailability. Although this review injected a molar excess of IGFBP-1 with IGF-1 to hypo- 
will discuss the individual actions of each protein, since physectomized rats and achieved some attenuation of 
they have usually been studied in isolation, it is important IGF-I action in stimulating rowth and sulfate incor- 
to remember that each cell type synthesizes multiple poration into cartilage [106]. These investigators used the 
forms of IGFBPs as well as IGFBP proteases. Therefore, nonphosphorylated form of IGFBP-I, suggesting that, if 
the target actions of any given form of IGFBP are regu- a high enough molar ratio is used, the phosphorylated 
lated by the abundance of that binding protein, its affinity form is not required to achieve inhibition. Two experi- 
for IGF-1 or IGF-II, the relative concentration of IGF-1 merits, using transgenic animals, have been reported. 
and -I| within that physiological f uid and the amount of D'Ercole and coworkers created a transgenic mouse 
proteolytic activity, strain in which there was high expression of IGFBP-I 
Another variable that is often overlooked is that most in the brain [107]. Since IGFBP-1 is not constitutively 
cell culture experiments are conducted by removing the synthesized in the brain, this resulted in a phar- 
conditioned culture medium from the cell cultures at the macological situation in which there were relatively high 
time of initiation of the experiment, thereby reducing the concentrations of IGFBP-1 compared to free IGF-I. 
soluble binding protein levels in the medium to zero, then Under these conditions, brain growth retardation was 
adding back IGF-I. This is a nonphysiological situation noted. Interestingly, although the IGFBP-1 levels that 
since IGFBPs are present in all interstitial fluids, and, were achieved in serum were ten times normal, the ani- 
therefore, changes in IGF-I in vivo occur on a background reals showed no somatic growth retardation, suggesting 
of some concentration of binding protein. Therefore, the that the molar excess of IGFBP-I to IGF-I in the brain 
use of established culture conditions will artificially was relatively greater than in the serum. The phos- 
increase free IGF-I and will not mimic the usual in z~ivo phorylation state of the IGFBP-1 in the brain or in the 
pericellular environment, serum was not determined. 
In a separate series of studies. Rajkumar and cowor- 
IGFBP-1 kers used a different promoter and achieved very high 
I GFBP-1 expression during fetal growth [108]. This pro- 
Inhibition of IGF actions moter was activated very early in fetal life and resulted 
in high IGFBP-1 levels in fetal tissues. Under these con- 
Addition of an excess of IGFBP-1 with IGF-I or IGF- ditions, these investigators achieved a small amount of 
I1 will result in inhibition of their actions if certain somatic growth retardation. The levels of IGFBP-I in 
requirements are met. The form of IGFBP-1 must be the serum were markedly elevated, at least tenfold greater 
highly phosphorylated or it must be added in a molar than they would have been under normal physiologic 
excess of at least a 4 : 1. In addition, using an assay system, conditions. These two experiments illustrate that if in 
in which the biological response can be quantified after a vitro conditions can be mimicked in in ~,iz'o models, e.g. 
relatively brief interval, will make it more likely that extremely high levels of IGFBP-1 relative to IGF-I, then 
inhibition will be detected. Thus, excess IGFBP-1 has growth attenuation can be observed. 
been shown to inhibit alpha aminoisobutyric a id (AIB) 
uptake in JEG-3 carcinoma cells and protein synthesis in 
muscle cells [102]. Likewise, it can inhibit IGF-I stimu- Simulation of IGF action 
lated glucose incorporation into Balb/c3T3 fibroblasts 
[103]. One experiment has shown that IGFBP-1 blocks When experiments are designed to mimic more closely 
IGF-I interaction with receptors on human endometrial the normal physiological ratio of lGF- I  to IGFBP-1, this 
membranes, uggesting that this is the principal mech- form of IGFBP can be shown to potentiate the effects of 
anism by which inhibition occurs [104]. Highly phos- IGF-I. Specifically, when nonphosphorylated forms are 
phorylated forms of IGFBP-1 have been shown to inhibit added with a molar excess of IGF-I to IGFBP-I to por- 
3H-thymidine incorporation using prolonged incubation cine aortic smooth muscle or human fibroblast cultures 
times of 24-36 h. Similarly, it inhibits DNA synthesis there is a 5.5-fold enhancement of the effect of IGF-I 
in FRTL5 cells, chick pelvic embryo leaflets and chick on DNA synthesis [63, 109]. Under these conditions, 
embryo fibroblasts [105]. degradation and clearance of IGF-I have been inhibited 
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Table 2. IGFBP functions in vivo 
Binding protein Proposed function Animal model 
IGFBP-1 Molar excess inhibits IGF growth-promoting actions. Transgenic mice 
Inhibits insulin-like actions Hypophysectomized rats 
IGFBP-2 Enhances IGF-mediated splenic growth Normal rats 
Knockout mice 
IGFBP-3 Enhances IGF-I actions in bone muscle and visceral organ growth Hypox or oophorectomized rats 
Major carrier of IGF-I and IGF-II Transgenic mice 
IGFBP-4 Inhibits IGF actions ND 
IGFBP-5 Inhibits or enhances IGF actions depending upon its affinity ND 
Localizes IGF-I and -II in ECM ND 
IGFBP-6 Inhibits IGF-II actions preferentially 
ND: not determined. 
and the affinity of the binding protein is low enough phosphorylated recombinant IGFBP-1 with IGF-I to 
that it approximates that of the receptor, thus allowing skin incisions in rats showed an enhancement of wound- 
material that is bound to IGF to remain in equilibrium breaking strength by 33-40% if a molar ratio of IGF-I 
with receptors for a prolonged interval. Since a 36-h assay to IGFBP-1 of 4 : 1 or greater was used [113]. In contrast, 
is used, this may permit the presentation of IGF-I to its if phosphorylated IGFBP-1 was utilized, there was no 
receptor at a critical time during the cell cycle potentiating effect. Frost and Tang showed that the endo- 
progression. Maintenance of a more optimal receptor metrial stromal cell response to medroxyprogesterone 
number may also be attained with this type of exper- which induces luteinization and increases the secretion 
imental design since it has been shown that the addition of phosphorylated IGFBP-1 is associated with growth 
of high concentrations of free IGF-I to cells may result attenuation [114]. In contrast, the proliferative phase 
in down regulation of receptors, endometrium is associated with the secretion of non- 
IGF-I mutants that have a reduced affinity for IGFBPs phosphorylated IGFBP-1. This suggests that the phos- 
have also been used to illustrate this phenomenon, phorylat ionstateof lGFBP-1 maybe important f or local 
Specifically, in human fibroblasts, an IGF-I mutant hat control of IGF action. 
bound poorly to lGFBP-l  did not result in optimal stimu- More recently, Tsouboi et al. have reported that 
lation of DNA synthesis compared to wild type IGF-I IGFBP-1 enhances the effects of IGF-I in promoting 
[110]. Similarly, insulin which does not bind to IGF bind- healing of dermal ulcers in both normal rabbits and in 
ing proteins cannot mimic the full effect o f lGF- I  in many rabbits with diabetes. The rate of re-epithelization a d 
cell culture systems, even though it will achieve the same granulation tissue formation was stimulated, compared 
percentage binding to receptors and the same degree of to control animals that received IGF-I alone when an 
receptor activation of receptor tyrosine kinase if added IGF-I to nonphosphorylated IGFBP-1 ratio of 3 : 1 was 
in high enough concentration. This suggests that some used [115]. To date, no transgenic animals have been 
other effect of the IGF/ IGFBP complex is required ur- prepared with the mutant form IGFBP-1 that is non- 
ing DNA synthesis assays for optimal responsiveness, phosphorylated to determine if hypersecretion of this 
Koistinen et al. confirmed these findings in dermal fibro- form can accelerate growth. 
blasts, showing the IGF-I to IGFBP-1 molar ratios 
between 2 : 1 and 25 : 1 resulted in an increase in the 3H- IGF-independent actions 
thymidine incorporation response [111]. 
Kratz et al. showed that an equimolar or higher ratio As pointed out previously, IGFBP-1 contains an RGD 
was used, that IGFBP-1 also enhanced the response of sequence and binds to the c~5fll integrin [59, 116]. The 
keratinocytes to IGF-I and that IGFBP-1 added alone functional significance of this interaction was shown by 
had no effect [112]. The phosphorylation state of IGFBP transfecting the IGFBP-1 cDNA into CHO cells. The 
has been shown to be important since phosphorylated cells that were expressing high concentrations of lGFBP- 
IGFBP-1 resulted in significant inhibition of the ability 1 migrated much more rapidly than cells that were trans- 
of human fibroblasts to respond to IGF-I with increased fected with vector alone. In addition, exogenous addition 
DNA synthesis, whereas dephosphorylated IGFBP-1 of pure IGFBP-1 to control cells resulted in enhanced 
resulted in potentiation i the same system [109]. migration. Since there was no response to IGF-I, this 
appeared to be a direct effect of IGFBP-1. To determine 
In vivo studies that the RGD sequence was required and that the inter- 
action was with the ~5j~l receptor, the cells were trans- 
Although in vivo studies showing the potentiation of fected with a mutant IGFBP-1 that contained a single 
IGF action are limited, several wound-healing studies substitution in amino acid position 221 converting the 
have shown that IGFBP-1 has a potentiation activity, arginine to tryptophan. The cells that were transfected 
Jyuan et al. reported that application of non- did not show any increase in their rate of migration. 
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Similarly, exogenously added [Trp 22~] IGFBP-1 did not actions of IGF-I. The addition of excess purified IGFBP- 
stimulate migration of nontransfected cells. 3 with IGF-I inhibits the insulin-like actions of IGF-I in 
Unlike IGFBP-1, we were not able to demonstrate hat Balb/c 3T3 cells [102]. The addition of excess IGFBP- 
the c~5//1 integrin could bind to IGFBP-2. In contrast o 3 to cultured fibroblasts inhibits their DNA synthesis 
this observation, Dehanty et al. have demonstrated that response to IGF-I with maximum inhibition noted at a 
IGF-potentiating activity can be demonstrated by 4:1 molar ratio of IGFBP-3 to IGF-I [124]. IGFBP-3 
IGFBP-2 and that this effect is lost when the RGD has also been shown in chick fibroblasts to inhibit IGF- 
sequence is modified in IGFBP-2 [117]. The integrin that I-stimulated DNA synthesis, and it also inhibits the effect 
mediates this effect has not been determined, of FGF on these cells, suggesting that it may have IGF- 
independent actions [125]. IGFBP-3 has been noted to 
IGFBP-2 inhibit IGF-I-stimulated steroidogenesis in rat granulosa 
cells and to inhibit cyclic AMP generation by IGF-I [126]. 
Inhibitory actions It also inhibits collagen synthesis in cultured rat osteo- 
blasts or mouse osteoblasts [127]. Although it inhibits 
IGFBP-2 concentrations in serum are induced by IGF- IGF-stimulated glucose uptake in porcine fat cells, it has 
I and inhibited by GH; therefore, its role in controlling no effect on insulin-stimulated uptake. 
IGF action is an important subject of analysis. Purified 
IGFBP-2 has been shown to inhibit DNA synthesis in 
chick embryo fibroblasts and rat astroglial cells [36, 118]. Potentiation of IGF action 
It is also an important inhibitor of IGF-II stimulated 
DNA synthesis in lung carcinoma cells. This inhibition Demello and Baxter first reported that, if IGFBP-3 
is believed to occur by inhibition of IGF binding the was associated with cell surfaces, it could stimulate DNA 
receptor since it inhibits binding to MDBK cells [119]. synthesis in human fibroblasts [65]. Pre-incubation of 
Des-IGF-I does not bind to IGFBP-2 and stimulates the cultures with IGFBP-3 prior to IGF-I addition was 
DNA synthesis in MDBK cells. Its effect exceeds that required. Conover extended these observations to deter- 
of IGF-II, suggesting that IGFBP-2 is inhibiting this mine that, when IGFBP-3 was coincubated with increas- 
response. IGFBP-2 has also been shown to inhibit other ing concentrations of IGF-I, there was a dose-dependent 
functions of IGF-I, such as inhibition of protein break- increase in AIB uptake [100]. She has proposed that pro- 
down [119]. IGFBP-2 could inhibit completely the effect teolysis of IGFBP-3 or processing of the molecule on the 
of lGF- I  stimulating smooth muscle cells to migrate [116]. cell surface may be required for this response. Conover 
IGF-I stimulated collagen synthesis has been shown to has shown that IGF receptor down-regulation is pre- 
be inhibited by IGFBP-2 [120]. vented by preincubation of IGFBP-3, and this may be 
one mechanism whereby it enhances the effects of IGF- 
Stimulatory effects 1. Similarly, Ernst and Rodan reported that cell surface- 
associated IGFBP-3 could potentiate the effect of IGF-I 
In spite of these reports of inhibition, several para- and A1B uptake in rat osteoblasts [128]. Blum confirmed 
doxical observations have been noted. First, when IGF- these observations, showing that coincubating IGF-I 
I is administered to experimental nimals, there is a large with IGFBP-3 results in a 90% increase in DNA synthesis 
increase in IGFBP-2, suggesting that it may not always in BHK cells [129]. Proteolysis of IGFBP-3 also may be 
be inhibiting IGF action. Second, gene knockout animals important. Schmidt et al. have shown that the 30-kDa 
in whom IGFBP-2 has been deleted have small spleens fragment of IGFBP-3 that is generated by a protease 
compared to control animals, suggesting that the known results in potentiation of the effect of IGF-I on osteobtast 
effect of IGF-I on inducing splenic enlargement in normal DNA synthesis [126]. 
animals may be due, in part, to enhanced expression of Administration of IGFBP-3 and 1GF-i to rat wounds 
IGFBP-2 [121]. In t,itro, Bar et al. showed that partially results in accelerated healing [130]. The combination of 
purified IGFBP-2 enhanced the effect of IGF-I on glucose IGFBP-3 and IGF-I is anti-catabolic and functions better 
transport and AIB uptake in microvascular epithelial than administration of IGF-I alone to GH deficient rats 
cells [122]. Whether this is a direct effect of IGFBP-2 or [131]. The studies of Bagi et al. have shown that admin- 
IGF-I bound to IGFBP-2 was not determined. Bovine istration of lGF- I  plus IGFBP-3 to oophorectomized rats 
IGFBP-2 was also shown to potentiate the replication results in the stimulation of growth and an increase in 
response to IGF-I by smooth muscle cells by approxi- bone mineral density [132]. This increase is dependent 
mately 80% [123]. upon dose and equimolar administration of IGF-I and 
IGFBP-Y Stewart et al. have shown that a polyclonal 
IGFBP-3 antibody to IGF-I that functions similarly to IGFBP- 
3 in prolonging IGF half-life in plasma results in the 
Inhibition oflGFaction potentiation of IGF-I-stimulated growth in hypo- 
physectomized rats [133]. In contrast, in Snell dwarf mice, 
Because of its role of carrying IGFs in serum, IGFBP-3 administration of a molar excess of IGFBP-3 with IGF- 
has been an important focus of modulating the endocrine I results in the inhibition of the IGF-I-stimulated growth 
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response [134]. Administration of an IGF analog to pigs of IGFBP-4 is an important post-translational modi- 
that binds poorly to IGFBP-3 did not result in growth fication. Fibroblasts and smooth muscle cells have been 
stimulation. Interestingly, overexpression f IGFBP-3 in shown to release IGFBP-4 proteases [143, 144]. Fol- 
tissues also may enhance the effects of IGF-I. IGFBP-3 lowing proteolytic leavage, there is an increase in the 
transgenic animals show visceral tissue enlargement. AIB uptake or DNA synthesis responses to IGF-I in 
IGF-I is known to be anti-apoptotic to breast epithelial these test systems. The proteolytic leavage site in rat 
cells. Transfection of breast epithelium with a tissue- IGFBP-4 has been identified and is between residues 
specific IGFBP-3 promoter esulted in inhibition of the K120 and H121 [61]. There is also a secondary site 
normal involution that occurs when rat pups are with- between residues M131 and K132 [145]. Mutagenesis of 
drawn during lactation [135]. This suggests, but does not these cleavage sites with readdition of a mutant hat is 
prove, that IGFBP-3 is acting locally to potentiate the resistant to proteolysis hows that the protease-resistant 
effects of IGF-I in inhibiting apoptosis, mutant is more active in inhibiting IGF-I action. No in 
vivo studies of IGFBP-4 action have been reported to 
IGF independent effects date. In summary, IGFBP-4's main role is to protect 
cells from over-stimulation by the IGFs and possibly to 
Direct effects of IGFBP-3 on cell growth have also been accelerate their clearance. 
reported. Transfection of Balb/c3T3 cells with IGFBP- 
3 cDNA results in inhibition of their DNA synthesis IGFBP-5 
independently of IGF-I. IGFBP-3 has also been shown 
to attenuate the effects of FSH on granulosa cell function Inhibition of IGF action 
directly and to inhibit the response of mouse embryo 
fibroblasts to serum or FGF [124, 136]. More recently, Addition of molar excess of IGFBP-5 to cell lines that 
the inhibitory effects of TGF-fl on breast carcinoma cell do not secrete IGFBP-5 protease generally results in inhi- 
division have been shown to be mediated through an bition of IGF actions. Keifer et al. showed that IGFBP- 
induction of IGFBP-3. Oh et al. have shown that addition 5 can inhibit IGF-I stimulation of DNA and glycogen 
of IGFBP-3 or truncated fragments that do not bind to synthesis in human osteosarcoma cells [146]. Wang et al. 
IGF-I to HS578T human breast cancer cells results in the showed inhibition of steroidogenesis in granulosa cells 
inhibition of DNA synthesis independently of its effects [147]. 
on IGF-I actions [137]. These investigators have purified 
a group of cell surface proteins that bind to IGFBP-3 Potentiation of IGF activity 
and have preliminary reported amino acid sequence data, 
suggesting that IGFBP-3 may have its own receptor on Multiple investigators have reported stimulation of 
the cell surface, which mediates these actions [138]. IGF action. When IGFBP-5 is allowed to associate with 
fibroblast ECM, and then fibroblasts are replated on top 
IGFBP-4 of this matrix, it can result in a two-fold enhancement of 
IGF action [66]. Since the affinity of IGFBP-5 for IGF-I is 
IGFBP-4 is the only form of IGF binding protein lowered eight-fold after ECM association, and the IGF- 
that has been shown to consistently inhibit IGF-I action, bound IGFBP-5 is in a more favorable quilibrium with 
Although there is minimal IGFBP-4 in serum, substantial receptors, this affinity shift presumably accounts for this 
concentrations may exist in some pericellular fluids, effect. Bautista et al. have shown that IGFBP-5 potent- 
IGFBP-4 does not have any of the properties associated luted the effect of IGF-I on osteoblast growth and protein 
with lowering of IGFBP affinity, such as cell surface synthesis [148]. Andress et al. also reported this effect 
association or dephosphorylation. It does undergo pro- for osteoblasts and have shown that a 22-kDa IGFBP-5 
teolytic cleavage, and the fragments do not bind IGF-I fragment hat is generated by proteolysis also directly 
or -II. stimulates DNA synthesis n these cells independently of 
Mohan et al. originally showed IGFBP-4's ability to IGF-I [149]. Whether this fragment isbinding to a unique 
inhibit the effect of IGF-I on chick pelvic cartilage growth receptor is unknown; however, they have reported a 300- 
[139]. Inhibition was does-dependent and required a kDa protein present on the surface of these cells that 
molar excess of IGFBP-4. Similarly, Ui et al. showed that binds to IGFBP-5 and the 22-kDa fragment [150]. Con- 
IGFBP-4 could inhibit steroidogenesis in rat granulosa over has reported ata that IGF-I binding to IGFBP-5 
cells [140], and Coulouscou et al. showed its ability to inhibits proteolysis of binding protein, although the need 
inhibit DNA synthesis in HD-29 colon carcinoma cells for proteolysis of IGFBP-5 for potentiation of IGF-I 
[141]. Other IGF-I stimulated ifferentiated functions DNA stimulated synthesis has not been definitively estab- 
that have been shown to be inhibited are cyclic AMP lished [151]. 
generation i osteoblasts, protein synthesis in B104 cells, Since the ability of IGFBP-5 to potentiate IGF action 
glycogen synthesis in osteosarcoma cells and steroido- on smooth muscle cells, fibroblasts or osteoblasts results 
genesis in granulosa cells in response to FSH [142]. It is from its ability to bind to ECM, understanding the fac- 
also a potent inhibitor of IGF-I-stimulated DNA syn- tors in ECM and the regions of IGFBP-5 that are necess- 
thesis in smooth muscle cells [143]. Proteolytic leavage ary for ECM association is important. Proteoglycans are 
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a major component of the ECM that binds to IGFBP-5. dence for a carrier protein. Arch Biochem Biophys 1975, 
168, 638-645. 
Glycosaminoglycans, uch as heparin and heparan 2. Hintz RL, Liu F. Demonstration of specifc plasma pro- 
sulfate, bind to IGFBP-5, whereas chondroitin sulfate tein binding sites for somatomedin. J Clin Endocr Metal) 
A and C have no activity [100]. This suggests that the 1977, 45, 988-995. 
glycosaminoglycan structure that is necessary for this 3. Furlanetto RW. Somatomedin binding protein: Evidence 
binding is conferred by O-sulfation of the 2 and 3 pos- for heterogenous subunit structure. J Clin Endocr Metah 
1980, 51, 12-19. 
itions of the iduronic acid ring. The region between amino 4. Drop SLS, Kortleve DJ, Guyda HJ. Isolation of a sore- 
acids 201 and 218 in ]GFBP-5 contains 10 out of 18 atomedin-binding protein from preterm amniotic fluid. 
amino acids that are basic. Competitive binding studies Development of a radioimmunoassay. J Clin Endoer 
with peptides and mutants have shown that this region Metab 1984, 59, 899-907. 
contains the GAG binding domain that is required for 5. Povoa G, Enberg G, Jornvall H, Hall K. Isolation and 
characterization f a somatomedin binding protein from ECM association [152]. Mutagenesis of key residues in 
mid term human amniotic fluid. Eur J Biochem 1984, 144, 
this area, principally amino acids 207, 214 and 218, results 199 204. 
in nearly complete loss of its affinity for either gly- 6. Brewer MT, Stetler GL, Squires CH, Thompson RC, 
cosaminoglycan of ECM [152, 153]. Proteoglycans often Busby WH, Clemmons DR. Cloning, characterization a d 
bind to basic residues and, therefore, may be the principle expression of a human insulin-like growth factor binding 
ECM binding component. IGFBP-5 also binds to ECM protein. Biochem Biophys Res Commun 1988, 152, 1289 
1297. 
by binding plasminogen activator inhibitor-I and 7. Lee YL, Hintz RL, James DM, Lee PDK, Shively JE, 
vitronectin. Association of the PAI-I vitronectin complex Powell DR. Insulin like growth factor IGF binding protein 
with IGFBP-5 maybe an important mechanism for its complementary deoxyribonucleic a id from human Hep 
stabilization within ECM. G2 hepatoma cells: predicted protein sequence suggests 
and IGF binding domain different from those of IGF-I 
and IGF-II receptors. Molec Endocr 1988, 3, 404411. 
IGFBP-6 8. Brown AL, Chiariotti L, Orlowski CC, et al. Nucleotide 
sequence and expression ofa cDNA clone encoding afetal 
In vivo studies of IGFBP-6 are quite limited. It may rat binding protein for insulin-like growth factors. J Biol 
have an anti-gonadotropin effect in the ovaries since it Chem 1989, 264, 5148 5154. 
inhibits effects of FSH and LH combined in the ster- 9. Martin JL, Baxter RC. Insulin like growth factor binding 
oidogenesis response to IGF-I.  In addition, it has been protein from human plasma, purification and charac- 
terization. J Biol Chem 1986, 261, 8754-8760. 
shown in bone that IGFBP-6 is regulated rather uniquely, 10. Wood, WI, Cachianes G, Henzel W J, et al. Cloning and 
which suggests that it may be an important modulator of expression of the GH dependent insulin like growth factor 
IGF- I I  action in this tissue, binding protein. Molec L~doer 1988, 2, 1176-1185. 
11. Shimasaki S, Shimonaka M, Zhang HP, Ling N. ldenti- 
SUMMARY fication of five different insulin-like growth factor binding 
proteins (IGFBPs) from adult rat serum and molecular 
The IGF-binding proteins are important modulators cloning of a novel IGFBP in rat and human. ,l Biol Chem 
199 I, 266, 10,646-10,653. 
of IGF action. They function to control the half-life of 12. Drop SLS, Kortleve DJ, Guyda HJ, Posner BI. lmmu- 
IGF-I  and -II in blood, their distribution among tissues noassay of a somatomedin-binding protein from human 
and extracellular fluids and, most importantly, the ability amniotic fluid: levels in fetal, neonatal, and adult sera. J 
Clin Endocr Metab 1984, 59, 908 915. of IGF-I  or IGF- I I  to associate with cell surface recep- 
13. Baxter RC, Martin, JL. Radioimmunoassay of growth tors. Since equilibrium in extracellular fluids almost hormone dependent insulin-like growth /'actor binding 
always favors binding to the IGFBPs as opposed to the protein in human plasma. J Clin lm:est 1986, 78, 150+ 
IGF receptors, these proteins function as important 1512. 
modulators of IGF action. Variables that alter their 14. Baxter RC. Physiological roles of the [GF binding 
affinity, such as proteolysis, adherence to cell surfaces proteins, In Spencer EM ed. Modern Concepls o[ Insulin- 
like Growth Factors. New York, Elsevier, 1991, 371 380. 
or extracellular matrix and phosphorylation, may be an 15. Streck RD, Wood TL, Hsu MS. Pintar JE. Insulin-like 
important means for controlling the release of IGF to growth factor I and I1 and insulin-like growth factor bind- 
receptors. Since the concentrations in these proteins and ing protien-2 mRNAs are expressed in adjacent issues 
extracellular fluids may be regulated either coordinately within rat embryonic and fetal limbs. De~" Biol 1992, 151, 
586 596. 
or independently of the factors that regulate the IGFs, 16. Jennische E, Skottner A, Hansson HA. Dynamic hanges 
this provides an important additional level of control of in insulin-like growth factor I immunoreactivity correlate 
the degree of exposure of cells to this potent mitogen, with repair events in rat ear after freeze- thaw injury. Exp 
In spite of much in vitro evidence to support these Molec Pathol 1987, 47, 193-201. 
conclusions, in vivo experiments, using transgenic or gene 17. Behringer RR, Lewin TM, Quaife C J, Palmiter RD, Brin- 
stre RL, D'Ercole AJ. Expression of insulin-like growth 
targeting techniques, are only beginning to emerge. This factor l stimulates normal somatic growth in growth hor- 
will be an important area for future investigation, mone deficient ransgenic mice. Endocrinology 1990, 127, 
1033 1040. 
REFERENCES 18. DeChiara RM, Efstratiadis A, Robertson EJ. A growth 
deficiency phenotype in heterozygous mice carrying an 
I. Zapf J, Waldvoge[ M, Froesch ER. Binding of non- insulin-like growth factor II gene disruption. Nature 1990, 
suppressible insulin-like activity to human serum: Evi- 345, 78 80. 
58 D.R. Clemmons 
19. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis Peptide Growth Factors and Their Receptors. Berlin, 
A. Mice carrying small mutations of the genes encoding Springer, 1993, 263-287. 
insulin like growth factor I (IGF-I) and type 1 IGF recep- 37. Baxter RC, Martin JL. Structure of the MT 140,000 
tor (IGF/r). Cell 1993, 75, 73-82. growth hormone-dependent insulin-like growth factor 
20. Camacho-Hubner C, Busby WH, McCusker RH, Wright binding protein complex: determination by reconstitution 
G, Clemmons DR. Identification of the forms of insulin- and affinity labeling. Proc Natl Acad Sci USA 1989, 86, 
like growth factor binding proteins produced by human 6898-6902. 
fibroblasts and the mechanisms that regulate their 38. Guler H-P, Zapf J, Schmid C, Froesch ER. Insulin-like 
secretion. J Biol Chem 1992, 267, 11,949-11,956. growth factors I and II in healthy man. Estimations of 
21. Cerro JA, Grewal A, Wood TL, Pintar JE. Tissue-specific half-lives and production rates. Acta Endocr 1989, 121, 
expression of insulin-like growth factor binding protein 753-758. 
(IGFBP) mRNAs in mouse and rat development. Regul 39. Dai J, Baxter RC. Regulation of acid labile subunit of 
Peptide 1993, 48, 189-198. the rat serum insulin-like growth factor binding protein 
22. Rechler MM. Insulin like growth factor binding proteins, complex. Endocrinology 1994, 135, 1066-1072. 
Vitamins and Hormones 1993, 47, 1-114. 40. Hodgkinson SC, Davis SR, Moore LG, Henderson HV, 
23. Hossenlopp P, Seurin D, Segovia B, Portolan G, Binoux Gluckman PD. Metabolic learance of insulin-like growth 
M. Heterogeneity of insulin-like growth factor binding factor-II in sheep. J Endocr 1989, 123, 461-468. 
proteins and relationships between structure and affinity. 41. Dai J, Baxter RC. Regulation in vivo of acid labile subunit 
2. Forms released by human and rat liver in culture. Eur of the rat serum insulin like growth factor binding protein 
J Biochem 1987, 170, 133-142. complex. Endocrinology 1994, 135, 2335-2341. 
24. Unterman TG, Oehler DT, Murphy L J, Lacson RG. Mul- 42. Zapf J, Schmid C, Guler HP, et al. Regulation of binding 
tihormonal regulation of insulin like growth factor bind- proteins for insulin-like growth factors in humans: 
ing protein-1 in rat H4 liE hepatoma cells: the dominant Increased expression of IGF binding proteins during treat- 
role of insulin. Endocrinology 1991, 128, 2693-2701. ment of healthy adults and in patients with extrapancreatic 
25. Ooi GT, Tseng LY, Tran MQ, Rechler MM. Insulin rap- tumor. J Clin Invest 1990, 86, 952-961. 
idly decreases insulin-like growth factor-binding protein- 43. Camacho-Hubner C, Clemmons DR, D'Ercole AJ. Regu- 
1 gene transcription i streptozoticin-diabetic rats. Molec lation of insulin-like growth factor binding proteins in 
Endocr 1992, 6, 2219-2228. transgenic mice with altered expression of growth hor- 
26. Swanichkul A, Allander SV, Morris SL, Powell DR. Glu- mone and IGF-I. Endocrinology 1991, 129, 1201-1206. 
corticoids and insulin regulate xpression of the human 44. Daughaday WH, Kapadia M. Significance of abnormal 
gene for insulin like growth factor binding protein-1 serum binding of insulin-like growth factor II in the devel- 
through proximal promoter elements. Proc Natl Acad Sci opment of hypoglycemia n patients with non-islet cell 
USA 1994, 269, 30,835-30,841. tumors. Proc Natl Acad Sci USA 1989, 86, 6778-6782. 
27. Strauss DS, Takemoto CD. Effect of fasting on insulin- 45. Boni-Schnetzler M, Binz K, Mary J-L, Schmid C, Sch- 
like growth factor-I (IGF-I) and growth hormone receptor wander J, Froesch ER. Regulation of hepatic expression 
mRNA levels and IGF-1 gene transcription i rat liver, of IGF I and fetal IGF binding protein mRNA in strew 
Molec Endocr 1990, 4, 91 100. tozotocin-diabetic rats. Fedn Eur Biochem Socs Lett 1989, 
28. Adamo ML, Shao ZM, Lanau F, et al. Insulin like growth 251, 253-256. 
factor I (IGF-I) and retinoic acid modulation of IGF 46. Clemmons DR, Busby WH, Snyder DK. Variables con- 
binding proteins (IGFBPs). IGFBP-2, 3 and 4 gene trolling the secretion of insulin-like growth factor binding 
expression and protein secretion in a breast cancer cell protein-2 in normal human subjects. J Clin Endocr Metab 
line. Endocrinology 1992, 131, 1858-1866. 1991, 73, 727-733. 
29. Wood TL, Brown AL, Rechler MM, Pintar JE. The 47. Straus DS, Takemoto CD. Effect of dietary protein depri- 
expression pattern of an insulin like growth factor (IGF) vation insulin-like growth factor IGF-I and II, IGF bind- 
ing protein-2 and serum albumin gene expression i  the 
binding protein gene is distinct from IGF-II in mid ges- rat. Endocrinology 1990, 127, 1849-1860. 
tation embryo. Molec Endocr 1990, 4, 1257-1263. 48. Busby WH, Snyder DK, Clemmons DR. Radioim- 
30. Wood TL, Rogler L, Pintar JE. Targeted gene disruption munoassay of a 26,000 dalton plasma insulin like growth 
of the IGFBP-2 gene. Growth Regul 1993, 3, 5-8. binding protein: control by nutritional variables. J Clin 
31. Adamo ML, Bach MA, Roberts CT, LeRoith D. Regu- Endocr Metab 1988, 67, 1225-1230. 
lation of insulin IGF-I and IGF-II gene expression. In 49. Suwannichkul A, Allander SV, Morris SL, Powell DR. 
LeRoith D ed. Insulin-like Growth Factors: Molecular and Glucocorticoids and insulin regulate expression of the 
Cellular Aspects. Boca Raton, FL, CRC Press, 1990, 271- human gene for insulin-like growth factor binding protein- 
303. 1 through proximal promoter elements. J Biol Chem 1996, 
32. Walker JL, Ginalska-Malinowska M, Romer TC, Puc- 269, 30,835-30,841. 
ilowska JB, Underwood LE. Effects of infusion of insulin- 50. O'Brien RM, Lucas PC, Forest CD, Magneson MH, 
like growth factor-I in a child with growth hormone insen- Granner DK. Identification of the sequence in the PEPCK 
sitivity syndrome. N Engl J Med 1991, 324, 1483-1488. gene that mediates the systemic effect of insulin on tran- 
33. Baxter RC, Martin JL. Binding proteins for insulin-like scription. Science 1990, 249, 533-537. 
growth factors: structure, regulation and function. Progr 51. Bar RS, Boes M, Clemmons DR, et al. Insulin differ- 
Growth Fact Res 1989, 1, 49-68. entially alters transcapillary movement of intravascular 
34. Takenada A, Miura Y, Mori A, Hirosawa M, Kato H, IGFBP-1, IGFBP-2 and endothelial cell IGF binding pro- 
Noguchi T. Distribution ofmRNAs of insulin-like growth teins in rat heart. Endocrinology 1990, 127, 497-499. 
factor binding proteins 1 and 3 between parenchymal nd 52. Lewitt MS, Sanders H, Baxter RC. Bioavailability ofinsu- 
non-parenchymal ce ls in the liver. J Biol Chem 1991, 55, lin like growth factors (IGF's) in rats determined by 
1191-1193. molecular distribution of human IGF binding protein-3. 
35. Booth BA, Bar RS, Boes M, Dake BL, Bayne ML, Cas- Endocrinology 1993, 133, 1797-1802. 
cieri MA. Intrinsic bioactivity of insulin-like growth factor 53. Senevirantre C, Jiangming L, Murphy LJ. Transcriptional 
binding proteins from endothelial cells. Endocrinology regulation of rat insulin like growth factor binding pro- 
1990, 6127, 2630-2638. tein-1 expression by growth hormone. Molec Endocr 1990, 
36. Rechler MM, Nissley SP. Insulin-like growth factors. In 4, 1199-1204. 
Role of IGF Binding Proteins in ]GF Actions 59 
54. Luo J, Murphy LJ. Dexamethasone i hibits growth hor- 70. Hossenlopp P, Segovia B, Lassare C, Roghani M, Bredon 
mone induction of insulin-like growth factor-I (IGF-I) M, BinouxM. Enzymatic evidence of degradation ofinsu- 
messenger ribonucleic acid (mRNA) in hypo- lin-like growth factor binding protein in 150 k complex 
physectomized rats and reduces IGF-I mRNA abundance during pregnancy. J Clin Endocr Metab 1990, 71, 797 
in the intact rat. Endocrinology 1989, 125, 165-171. 805. 
55. Ooi GT, Orlowski, CC, Brown AL, Becker RE, Unterman 71. Guidice LC, Farrell EM, Pham H, Lamson FG, Rosenfeld 
TG, Rechler MM. Different tissue distribution and hor- RG. Insulin like growth factor binding proteins in 
monal regulation of messenger RNAs encoding rat insu- maternal serum throughout gestation and in the puer- 
lin-like growth factor binding proteins-1 and 2. Molec perium. J Clin Endocr Metab 1990, 71,806-816. 
Endocr 1990, 4, 321 328. 72. Davenport ML, Clemmons DR, Miles MV, Camacho- 
56. O'Brien RM, Noisen RL, Sandwich L, et al. Hepatic mere- Hubner C, D'Ercole A J, Underwood LE. Regulation of 
brane factor 3 and hormone regulated responsiveness of serum insulin-like growth factor I (IGF-I) and IGF bind- 
PEPCK and insulin-like growth factor binding protein-I ing proteins during rat pregnancy. Endocrinology 1990, 
genes. Molec Cell Biol 1994, 203, 1835-1841. 127, 1278-1286. 
57. Honda Y, Landale EC, Strong DD, Baylink DJ, Mohan 73. Fowlkes J, Enghild J J, Suzukik N, Nagase H. Matrix 
S. Recombinant synthesis of insulin-like growth factor metalloproteases degrade insulin like growth factor bind- 
binding protein-4: Development of a radioimmunoassay ing protein-3 in dermal fibroblast cultures. J Biol Chem 
for IGFBP-4 in human serum and other biological fluids. 1994, 269, 25,742 25,746. 
J Clin Endocr Metab 1996, 81, 1389-1396. 74. Bang P, Brismar K, Rosenfeld RG, Hall K. Fasting affects 
58. Binoux M, Roghani M, Hassenlopp P, Harudin S, Gour- serum insulin-like growth factor (1GFs) and IGF binding 
melen M. Molecular forms of human IGF binding pro- proteins differently in patients with NIDDM versus non- 
teins: Physiological implications. Acta Endocr 1991, 124 obese and obese weight matched healthy subjects. J Cl#l 
(Supp 2), 41-47. Endocr Metab 1994, 78, 960-966. 
59. Zapf J, Keifer MC, Merryweather J, et al. Isolation from 75. Fielder P J, Guevara-Aguirre J, Rosenbloom AL, Carlsson 
adult human serum forms of insulin-like growth factor L, Hintz RE, Rosenfeld RG. Expression of insulin-like 
binding proteins and molecular cloning of one of them growth factors, 1GF binding proteins and growth hor- 
that is increased by IGF-I administration. J Biol ('hem mone binding proteins in heterozygous relatives of Ecu- 
1990, 265, 14,892-14,898. adorian GH receptor deficient patients. J Clin Endocr 
60. Jones JI, Gockerman A, Busby WH, Jr, Wright G, Clem- Metab 1992, 74, 743-750. 
mons DR. Insulin-like growth factor binding protein 1 76. Cwyfan-Hughes SC, Cotterill AM, Molloy AR. Induction 
stimulates cell migration and binds to the e5fll integrin by of specific proteases for insulin-like growth factor binding 
means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci protein following major heart surgery. J L)Idocr 1992, 135, 
USA 1993, 90, 10,553 10,557. 135 145. 
61. Chernausek SD, Smith CE, Duffin KL, Busby WH, 77. Davenport ML, Isley WL, Pucilowska J. et al. Insulin- 
Wright G, Clemmons DR. Proteolytic leavage of insulin like growth factor binding protein-3 proteolysis i induced 
like growth factor binding protein-4 (IGFBP-4). J Biol following elective surgery. J Clin Endocr Metab 1992, 130, 
Chem 1995, 270, 11,377-11,382. 2505 2512. 
62. Jones JI, D'Ercole A J, Camacho-Hubner C, Clemmons 78. Blat C, Villaudy J, Binoux M. In eit:o proteolysis of serum 
DR. Phosphorylation finsulin-like growth factor binding insulin-like growth factor binding protein-3 results in 
protein in cell culture and in vivo: effects on affinity for minimal availability of IGF to target cells. J Clin lnrest 
IGF-I. Proc Natl Acad Sci 1991,88, 7481-7485. 
63. Elgin RG, Busby WH, Clemmons DR. An insulin-like 1994, 93, 2286-2290. 
growth factor binding protein enhances the biologic 79. Cohen P, Graves HC, Peehl D, Kamasei M, Guidice LC, 
Rosenthal RG. Prostate specific antigen PSA is an insulin- response to IGF-I. Proc Natl Acad Sci USA 1987, 84, 
3254-3258. like growth factor binding protein-3 protease found in 
64. McCusker RH, Camacho-Hubner C, Bayne ML, Cascieri seminal plasma 2. Clin Endocr Metab 1992, 75, 1046-1054. 
MA, Clemmons DR. Insulin-like growth factor (IGF) 80. Conover CA, DeLeon DD. Acid-activated insulin-like 
binding to human fibroblast and glioblastoma cells: The growth factor binding protein-3 proteolysis in normal and 
modulating effect of cell released IGF binding proteins transformed cells: role of cathepsin-D. J Biol Chem 1994, 
(IGFBPs). J Cell Physiol 1990, 144, 244-253. 269, 7076 7080. 
65. DeMellow JSM, Baxter RC. Growth hormone dependent 81. Lalou C, Binoux M. Evidence that proteolysis of insulin- 
insulin-like growth factor binding protein both inhibits like growth factor binding protein-3 occurs in the normal 
and potentiates IGF-I stimulated DNA synthesis in skin state outside of the bloodstream. Re.qul Pept 1993, 48, 
fibroblasts. Biochem Biophys Res Commun 1988,156, 199- 179-188. 
204. 82. Gargosky SE, Pham H. Wilson KF, Liu F, Guidice LC, 
66. Jones Jl, Gockerman A, Busby WH, Camacho-Hubner Rosenfeld RG. Measurement and characterization of 
C, Clemmons DR. Extracellular matrix contains insulin- insulin-like growth factor binding protein-3 in human bio- 
like growth factor binding protein-5: potentiation of the logic fluids discrepancy between radioimmunoassays nd 
effects of IGF-1. J Cell Biol 1993, 121, 679-687. ligang blotting. Endocrinology 1992, 131, 3051 3060. 
67. Clemmons DR, Underwood LE, Chatelain PG, Van Wyk 83. Davenport ML, Pucilowska J, Clemmons DR, Lundblad 
JJ. Liberation of immunoreactive somatomedin-C from R, Spencer JA, Underwood LE. Tissue specific expression 
its binding proteins by proteolytic enzymes and heparin, of IGFBP-3 protease activity during rat pregnancy. Endo- 
J Clin Endocr Metab 1983, 56, 384-389. crinoloqy 1992, 75, 590-595. 
68. Lassare C, Binoux M. Insulin-like growth factor binding 84. McCusker RH, Campion DR, Jones WK, Clemmons DR. 
protein-3 is functionally altered in pregnancy plasma. The insulin-like growth factor-binding proteins of porcine 
Endocrinology 1994,134, 1254-1262. serum: endocrine and nutritional regulation. Endo- 
69. Lee CY, Rechler MM. Proteolysis of insulin-like growth crinoloqy 1989, 125, 501-509. 
factor binding protein-3 in 150 kilodalton IGFBP corn- 85. Pucilowska JB, Davenport ML, Kabir I, et al. The effect 
plexes by a cation dependent protein activity in adult rat of dietary protein supplementation insulin like growth 
serum promotes the release of IGF-I. Endocrinology 1995, factors (IGF's) and IGF binding proteins in children with 
! 36, 4982-4989. shigellosis. J Clin Endocr Metah 1993, 77, 1516-1521. 
60 D.R. Clemmons 
86. Gockerman A, Clemmons DR. Porcine aortic smooth 103. Okajina T, Iwashita M, Takeda Y, et al. Inhibitory effects 
muscle cells secrete a serine protease for insulin like growth insulin-like growth factor binding proteins 1 and 3 on 
factor binding protein-2. Circ Res 1995, 76, 514-521. IGF activated glucose consumption i mouse Balb/c3T3 
87. Nam TJ, Busby WH, Clemmons DR. Human fibroblasts fibroblasts. J Endocr 1993, 133, 457-470. 
secrete a serine protease that cleaves insulin like growth 104. Rutanen E-M, Pekonen F, Makinen T. Soluble 34 K bind- 
factor binding protein-5. Endocrinology 1994, 135, 1385- ing protein inhibits the binding of insulin-like growth fac- 
1391. tor I to its own well receptors in human secretory phase 
88. Andress DL, Birnbaum RS. Human osteoblast-derived endometrium: evidence for autocrine/paracrine regulation 
insulin-like growth factor (IGF) binding protein-5 stimu- of growth factor action. J Clin Endocr Metab 1988, 66, 
lates osteoblast mitogenesis and potentiates IGF action. J 173-180. 
Biol Chem 1992, 267, 22,467-22,472. 105. Frauman AG, Tsuzaki S, Moses AC. The binding charac- 
89. Thrailkill KM, Quarles ID, Nagase H, Suzuki K, Serra teristics and biological effects in FRTL5 cells of placental 
DM, Fowlkes JL. Characterization f insulin-like growth protein-12, and insulin-like growth factor-binding protein 
binding protein-5 degrading proteases produced through- purified from human amniotic fluid. Endocrinology 1989, 
out murine osteoblast differentiation. Endocrinology 1995, 124, 2289-2296. 
136, 3527-3534. 106. Cox GN, McDermott MJ, Merkel E, et al. Recombinant 
90. NamTJ, BusbyWH, Jr, Clemmons DR. Characterization human insulin-like growth factor binding protein-1 
and determination f the relative abundance of two types inhibits growth stimulated by IGF-I and growth hormone 
of IGFBP-5 proteases that are secreted by human fibro- in hypophysectomized rats. Endocrinology 1994, 35, 1913- 
blasts. Endocrinology in press. 1920. 
91. Cheung PT, Wu J, Banach W, Chernausek S. Glu- 107. D'Ercole AJ, Dai Z, Xing Y, et al. Human insulin-like 
cocorticoid regulation of insulin-like growth factor bind- growth factor binding protein-1 (hlGFBP-1) transgenic 
ing protein-4 protease by a rat neural cell line, mice: characterization a d insights into the regulation of 
Endocrinology 1994, 135, 798-806. IGFBP-1 expression. Devl Brain Res 1994, 82, 213-222. 
92. Hassager CL, Fitzpatrick LA, Spencer EM, Riggs FL, 108. Rajkumar K, Barron D, Lewitt M, Murphy LJ. Growth 
Conover CA. Basal and regulated secretion of insulin-like retardation and hyperglycemia in insulin-like growth fac- 
growth factor binding proteins in osteoblast-like c lls is tor binding protein-1 transgenic mice. Endocrinology 1995, 
cell line specific. J Clin Endocr Metab 1992, 75, 228-233. 136, 4029-4034. 
93. Parker A, Gockerman A, Busby WH, Clemmons DR. 109. Busby WH, Klapper DG, Clemmons DR. Purification of 
Properties of an insulin like growth factor binding protein a 31000 dalton insulin-like growth factor binding protein 
4 protease that is secreted by smooth muscle cells. Endo- from human amniotic fluid. J Biol Chem 1988, 263, 
crinology 1995, 135, 2470-2476. 14,203 14,210. 
94. Durham SK, Keifer MR, Riggs BL, Conover CA. Regu- 110. Clemmons DR, Cascieri MA, Camacho-Hubner C, 
lation of insulin like growth factor binding protein-4 by a McCusker RH, Bayne ML. Discrete alterations of the 
specific insulin like growth factor binding protein-4 pro- IGF-I molecule that alter its affinity for IGF binding pro- 
tease in normal human osteoblast like cells. Implications teins result in changes in bioactivity. J Biol Chem 1990, 
on human cell physiology. J Bone Mineral Res 1994, 9, 265, 12,210-12,216. 
111-117. 111. Koistinen R, Itkinen P, Selenius P, Seppala M. Insulin 
95. Jones JI, Busby WH, Wright G, Smith CE, Kimack NM, like growth factor binding protein-1 inhibits binding of 
Clemmons DR. Identification of the sites of phos- IGF-1 on fetal skin fibroblasts but stimulates their DNA 
phorylation i  insulin-like growth factor binding protein- synthesis. Biochem Biophys Res Commun 1990, 173, 408- 
1: Regulation of its affinity by phosphorylation f serine 415. 
101. JBiolChem 1993, 268, 1125-1131. 112. Kratz G, Lake M, Ljungstrom K, Forsberg G, Hae- 
96. Ankrapp DP, Jones JI, Clemmons DR. Characterization gerstrand A, Gidlund M. Effect of recombinant IGF bind- 
of insulin like growth factor binding protein-I kinases ing protein-1 on primary cultures of human keratinocytes 
from human hepatoma cells. J Cell Biochem 1996, 60, 387- and fibroblasts: selective nhancement of IGF-I but not 
399. IGF-II induced cell proliferation. Exp Cell Res 1992, 202, 
97. Westwood M, Gibson JM, White A. Purification and 381-385. 
characterization f the IGFBP-1 phosphoform found in 113. Jyung RW, Mustoe T, Busby WH, Clemmons DR. 
normal plasma. Presented to the 5th International Insulin Increased wound breaking strength induced by insulin- 
and IGF Symposium. Abstract no. 14 1995, 3-5 March. like growth factor-1 in combination with IGF binding 
98. Hoeck WG, Mukku VR. Identification of the major sites protein-1. Surgery 1994, 115, 223-239. 
of phosphorylation i IGF binding protein-3. J Cell 114. Frost JP, Tseng LT. Insulin-like growth factor binding 
Biochem 1994, 56, 262-273. protein-1 is phosphorylated by cultured human endo- 
99. Baxter RC. Glycosaminoglycans i hibit formation of the metrial cells and multiple protein kinases in vitro. J Biol 
140 kDa insulin like growth factor binding protein Chem 1991,266, 18,082-18,088. 
complex. Biochem J 1990, 271, 773-777. 115. Tsuboi R, Shi CM, Sato C, Cox GN, Ogawa H. Coad- 
100. Conover CA. Potentiation of insulin-like growth factor ministration of insulin like growth factor (IGF-I) and IGF 
(IGF) action by IGF-binding protein-3: Studies of under- binding protein-1 stimulates wound healing in animal 
lying mechanism. Endocrinology 1992, 130, 3191-3199. models. J Invest Dermatol 1995, 104, 199-203. 
101. Arai T, Parker AJ, Busby WH, Clemmons DR. Heparin, 116. Gockerman A, Jones JI, Prevette T, Clemmons DR. Insu- 
heparan sulfate, and dermatan sulfate regulate formation lin like growth factor binding protein-2 inhibits smooth 
of the insulin-like growth factor-I and insulin-like growth muscle cell migration response to IGF-I. Endocrinology 
factor-binding protein complexes. J Biol Chem 1994, 269, 1995, 136, 4168-4173. 
20,388-20,393. 117. Delhanty PJD, Han VKM. An RGD to RGE mutation 
102. Ritvos O, Ranta T, Jalkanen J, et al. Insulin-like growth in the putative membrane binding domain of IGFBP-2 
factor (IGF) binding protein from human decidua inhibits inhibits its potentiation of IGF-II induced thymidine 
the binding and biological action of IGF-I in cultured uptake by SCP cell. Presented to the 75th Annual Meeting 
choriocarcinoma cells. Endocrinology 1988, 122, 2150- of the Endocrine Society. Las Vegas, NV. 1993, Abstract 
2157. 2256. 
Role of IGF Binding Proteins in 1GF Actions 61 
118. Knauer D J, Smith GL. Inhibition of biologic activity of 134. van Buul-Offers SC, Reijen-Gresnigt R, Bloenen R, Hoog- 
multiplication stimulating activity by binding to its carrier erbrugge C, van den Brande JL. Co-administration of 
protein. Proc Natl Acad Sci USA 1980, 77, 7252-7254. IGF-I binding protein-3 differentially inhibits IGF-I 
119. Ross M, Francis GL, Szabo L, Wallace JC, Ballard FJ. induced total body organ growth of Snell dwarf mice. 
Insulin-like growth factor (IGF)-binding proteins inhibit Pro9 r Growth Fact Res 1995, 6, 377 383. 
the biological activities of IGF-I and IGF-2 but not des- 135. Neuschwander S, Schwartz A, Wood TL, Roberts C, Hen- 
(I-3)-IGF-I. Biochem J 1989, 258, 267-272. ninghauser L, LeRoith D. Involution of the lactating 
120. Feyen JH, Evans DB, Binkert C, Heinrich GF, Gaisse S, mammary gland is inhibited by the IGF system in a trans- 
Koeher HP. Recombinant human CYS 281 insulin like genic mouse model. J Clin Invest 1996, 97, 2225-2232. 
growth factor binding protein-2 inhibits both basal and 136. Liu L, Delbe J, Blat C, ZapfJ, Harel L. Insulin-like growth 
insulin like growth factor I stimulated proliferation and factor protein-3 (IGFBP-3) is an inhibition of serum 
collagen synthesis in fetal rat calvaria. J Biol Chem 1991, growth factors other than IGF-I and IGF-Ii. J Cell Phv- 
266, 19,469 19,474. siol 1992, 153, 15 21. 
121. Pintar JE, Schuller A, Cerro JA, Czick M, Grewal A, 137. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin like 
Green B. Genetic ablation oflGFBP-2 suggests functional growth factor (1GF) independent actions of IGF binding 
redundancy in the IGFBP family, Progr Growth Fact Res protein-3 in HS578 in human breast carcinoma cells. J 
1995, 6, 437-445. Biol Chem 1993, 268, 14,964-14,971. 
122. Bar RS, Booth BA, Bowes M, Drake BL. Insulin-like 138. Oh Y, Muller HL, Pham H, Rosenfeld RG. Dem- 
growth factor binding proteins from cultured endothelial onstration of receptors of insulin-like growth factor bind- 
cells: Purification, characterization, and intrinsic biologic ing protein-3 on HS578T breast cancer cells. J Biol Chem 
activities. Endocrinology 1989, 125, 1910-1920. 1996, 268, 26,045-26,048. 
123. Bourner M J, Busby WH, Siegel NR, Krivi GG, McCusker 139. Mohan S, Bautista CM, Wergedal J, Baylink DJ. Isolation 
RH, Clemmons DR. Cloning and sequence determination of inhibitory insulin-like growth factor (IGF) binding pro- 
of bovine insulin-like growth factor binding protein-2 tein from bone cell conditioned medium: a potential local 
(IGFBP-2): comparison of it structural and functional regulator of IGF action. Proe Natl Acad Sci USA 1989, 
properties with IGFBP- 1. J Cell Biochem 1992, 48, 215- 86, 8338--8342. 
226. 140. Ui M, Shimonaka M. Shimasaki S, Ling N. An insulin- 
124. Btat C, Delbe J, Villaudy J, Chatelain PG, Golde A, Harel like growth factor-binding protein in ovarian follicular 
L. Inhibitory diffusible factor-45 bifunctional activity as a fluid blocks follicle-stimulating hormone-stimulated ster- 
cell growth inhibitor and as an insulin-like growth factor old production by ovarian granulosa cells. Emh)crinoh¥/v 
l-binding protein. J Biol Chem 1989, 264, 12,449 12,454. 1989, 125, 912-916. 
125. Villaudy J, Delbe J, Blat C, Desaulty G, Gole A, Harel L. 141. Coulouscou JM, Shoyab M. Purification of a colon cancer 
An IGF binding protein is an inhibitor of IGF stimulation, cell growth inhibitor and its identification as insulin-like 
J Cell Physiol 1991, 149, 492-496. growth factor binding protein-4. Cancer Res 1991, 51, 
126. Bicsak TA, Shimonaka M, Malkowski M, Ling N. Insu- 2813 2819. 
lin-like growth factor binding protein-3 inhibition ofgran- 142. Jones JI, Clemmons DR. Insulin like growth factor and 
ulosa cell function effect on cycle 3'5' monophosphate, their binding proteins: biologic actions. Endocr Rev 1995. 
deoxyribonucleic a id synthesis and comparison of effect 
of IGF-I antibody, k,)Tdocrinology 1990, 126, 2184~2189. 16, 3 34. 
143. Cohick WS, Gockerman A, Clemmons DR. Vascular 
127. Schmid C, Rutishauser J, Schlapfer I, Froesch ER, ZapfJ. smooth muscle cells synthesize two forms of insulin-like 
Intact but not truncated insulin-like growth factor binding growth factor binding proteins which are regulated iffer- 
protein-3 blocks IGF-I induced stimulation ofosteoblasts: 
control oflGFsignaHingto bone cellsby IGFBP-3 specific ently by the insulin like growth factors. J Cell Phvsio/ 
proteolysis. Biochem Biophys Res Commun 1991,179, 57% 1993, 157, 52 60. 
585. 144. Conover CA, Keifer MC, Zapf J. Post translational regu- 
lation of insulin like growth factor binding protein 4 in 128. Earnst M, Rodan GA. Increased activity of IGF-I osteo- 
blastic cells in the presence of GH: positive correlation normal and transformed human fibroblasts. J Clin Invest 
with the presence of GH induced IGFBP-3. Endocrinology 1993, 91, 1129 1137. 
1990, 127, 807 814. 145. Conover CA, Durham SK, Zapf J, Masiarz FR, Keifer 
129. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MC. Cleavage analysis of insulin-like growth factor 
MB, Bierich JR. Insulin-like growth factor I (IGF-I)bind- (IGF)-dependent IGF-binding protein-4 proteolysis and 
ing protein complex is a better mitogen than free IGE-I. expression of protease-resistant lGF-binding protein-4 
Endocrinology 1989, 125, 766 772. mutants. J Biol Chem 1995, 270, 4395-4400. 
130. SommerA, Maceck C, Spratt KS, etal. Molecular genetics 146, Keller MC, Schmid C, Waldvogel M, et a/. Charac- 
and actions of recombinant insulin like growth factor terization of recombinant human insulin-like growth fac- 
binding protein-3. In Modern Concepts o1 Insulin-like tot binding proteins-4, -5, and -6 produced in yeast. J Bio/ 
Growth Factors. New York, Elsevier, 1991, 715 728. Chem 1992. 267, 12,692 12,699. 
131. Clark PG, Mortensen D, Reigsupreder D, Mohler M, 147. Ling NC, Liu XJ, Malkowski M, Guo YL, Erickson GF, 
Etchevery T, Mukkev V. Recombinant human insulin like Shimasaki S. Structural and functional studies of insulin- 
growth factor binding protein 3: Effects on the glycine and like growth factor binding proteins in the ovary. Growth 
growth promotions activities ofrh 1GF-! in the rat. Growth Regul 1993, 3, 70 74. 
Regul 1993, 3, 46-50. 148. Bautista CM, Baylink DJ, Mohan S. Isolation of a novel 
132. Bagi CM, Brommage R, Adams SO, Rosen DM, Sommer insulin-like growth factor (IGF) binding protein from 
A. Benefit of systemically administered rh IGF-I and rh human bone: a potential candidate for fixing IGF-II in 
IGF-IIGBP-3 on cancellous bone in oophorectomized human bone. Biochem Biophys Res Commun 1991, 176, 
rats. J Bone Mineral Res 1994, 9, 1301 1312. 756 763. 
133. Stewart CH, Bates DC, Calder TA, Woddell SM, Pell JM. 149. Andress DL, Loop SM, Zapf J, Kiefer MC. Carboxy 
Potentiation of insulin like growth factor (IGF-I) activity truncated insulin like-growth factor binding protein-5 
by an antibody: supportive vidence for enhancement of stimulates mitogenesis in osteoblast like cells. Biochem 
IGF-I bioavailability in vivo by IGF binding proteins. Biophys Res Commun 1993, 195, 25 30. 
t~'ndocrinology 1993, 133, 1462 1465. 150. Andress DE. Heparin modulates the binding of insu- 
62 D.R. Clemmons 
lin/like growth factor (IGF) binding protein 5 to a mem- Effect of substitution of specific amino acids in insulin like 
brane protein in osteoblastic cells. J Biol Chem 1995, 270, growth factor binding protein-5 on heparin binding and 
28,289-28,296. its change in affinity for IGF-I in response to heparin. J 
151. Conover CA, Keifer MC. Regulation of biological effect Biol Chem 1996, 271, 6099-6106. 
of endogenous insulin like growth factor binding protein 153. Parker A, Busby WH, Clemmons DR. Identification of 
5 in human osteoblast cells. J Clin Endocr Metab 1993, 76, the extracellular matrix bonding site for insulin like 
1153-1159. growth factor binding protein-5. J Biol Chem 1996, 271, 
152. Arai T, Clarke S, Parker A, Busby WH, Clemmons DR. 13,523-13,529. 
